This pathological assessment suggests that the absence of SOCS2 does not appear to protect against the deterioration of mucosal integrity in DSS experimental colitis and therefore the improved bone health noted in the DSS-treated Socs2-deficient mice is unlikely to be solely attributed to improved disease status. Here, SOCS2 is linked to colitis.